Summit Therapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Summit Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 3 completed later-stage tilt top decile by trial count

Summit Therapeutics: 9 sponsored US clinical trials, 3 recruiting.

Summit Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 6 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 2 trials.

Top-decile sponsor footprint

Summit Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832
RECRUITING Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514
RECRUITING Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608
ACTIVE NOT RECRUITING Phase 3

Phase III Study of AK112 for NSCLC Patients

NCT06396065
TERMINATED Phase 3

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
COMPLETED Phase 3

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

NCT03595553
TERMINATED Phase 2

Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02858362
COMPLETED Phase 2

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

NCT02784002
COMPLETED Phase 2

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

NCT02092935

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 6

Therapeutic Areas

Non-Small Cell Lung Cancer 2
Non-squamous Non-small Cell Lung Cancer 1
Clostridioides Difficile Infection 1
Metastatic Colorectal Cancer (CRC) 1

Where Summit Therapeutics enrollment is open (later-stage tilt)

3 recruiting of 9 indexed (33% open); 3 completed (33%).

Phase mix: 6 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Non-Small Cell Lung Cancer (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Summit Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Summit Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Summit Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Summit Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Summit Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Summit Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Summit Therapeutics or any single study.

  • 3 of Summit Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Summit Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Summit Therapeutics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.